In May 2019 the Bulgarian Drug Agency (BDA) announced that after auditing the US FDA confirmed the BDA capacity and ability to perform GMP inspections equivalent to the US standards. On the basis of the sector agreement between the European Commission and the USA, there will be mutual recognition of GMP inspections of drug manufacturing […]
Posts Filtered by Category: GMP/GDP
Brexit: the exemption for quality control testing
In the end of February 2019, the European Commission (EC) produced a letter concerning the withdrawal of the United Kingdom from the perspective of the EU rules for batch testing of medicinal products. The EC communication addressed the option that exemptions could be granted by the competent authorities on case by case basis, allowing marketing […]
Bulgaria: managing alerts during verification and decommissioning of medicines
After February 9th 2019 the EU drug verification system (established by the Falsified Medicines Directive (Directive 2011/62/EU) and further detailed by Commission Delegated Regulation (EU) 2016/161) became applicable. The Bulgarian Drug Agency (BDA) and the Bulgarian Medicines Verification Organisation (BGMVO) published the first Guidelines for managing alerts during verification and decommissioning of medicines. The document […]
How to use the defective product report to notify a quality defect to the Romanian Drug Agency
The Romanian Drug Agency (ANMDM) published on their website scientific decision No 4/24.10.2018 implementing the document of European Medicines Agency (EMA) on the defective product report (EMA/INS/GMP/35037/2017). Marketing authorisation holders (MAHs) have to report to ANMDM all the non-conformities related to the quality of medicinal products authorised in Romania under MRP/DCP or purely national procedure. […]
Bulgarian Drug Agency: reduced timelines for manufacturing authorisations and wholesale distribution licenses
The Bulgarian Drug Law amendments were published on 12-Oct-2018 affecting the timelines which are legally set for the Bulgarian Drug Agency (BDA) to issue/refuse national manufacturing authorisations or wholesale distribution licenses. The previously provided 90 days are now reduced to 60 days. According to the Drug Law, in this timeframe the BDA should complete the […]
The Bulgarian Drug Agency initiates PIC/S membership procedure
The Bulgarian Drug Agency (BDA) announced that they will initiate the procedure to become a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). PIC/S is a non-binding, informal co-operative arrangement between Regulatory Authorities in the field of Good Manufacturing Practice (GMP) of medicinal products for human or veterinary use. PIC/S aims at harmonising inspection procedures […]